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Abstract
Background. Echocardiography is an established techni-
que to estimate the risk for cardiovascular complications in
patients with end-stage renal disease (ESRD). An enlarged
left atrium (LA) has recently emerged as a marker of adverse
cardiovascular outcomes in various pathologic conditions.
However, there have been few studies to evaluate its prog-
nostic value in patients with ESRD, particularly those re-
ceiving continuous ambulatory peritoneal dialysis (CAPD).
Methods. We conducted an observational cohort study to
investigate whether enlarged LA can predict patient out-
come in 216 patients with CAPD. Study outcomes were all-
cause and cardiovascular mortality.
Results. Increased left atrium volume index (LAVI > 32
mL/m2) was observed in 99 (45.8%) of the CAPD patients.
During the follow-up (26.3 6 18.6 months), 20 patients
(9.3%) died. Kaplan–Meier analysis revealed that the
5-year survival rate was significantly lower in patients with
LAVI > 32 mL/m2 than those with LAVI  32 mL/m2 (69
versus 82%, P ¼ 0.024). In multivariate analyses adjusted
for echocardiographic parameters and clinical and labora-
tory data, increased LAVI was an independent predictor of
all-cause mortality [hazard ratio (HR) 1.05, 95% confi-
dence interval (CI) 1.01–1.10, P ¼ 0.03] and cardiovascu-
lar mortality (HR 1.08, 95% CI 1.02–1.14, P ¼ 0.006).
Furthermore, increased LAVI provided the highest predic-
tive value for all-cause mortality [area under the receiver
operating characteristic curve (AUC) ¼ 0.766, P < 0.001]
and cardiovascular mortality (AUC ¼ 0.836, P < 0.001)
among the measured echocardiographic parameters.
Conclusions. We showed that increased LAVI predicted
adverse outcomes better than other echocardiographic pa-
rameters in patients with CAPD.
Keywords: CAPD; echocardiography; left atrial volume; mortality
Introduction
Echocardiography is an established technique used to esti-
mate the risk for cardiovascular complications and to guide
treatment in patients with end-stage renal disease (ESRD)
[1]. Among the many parameters measured by this techni-
que, left ventricular mass index (LVMI), ejection fraction
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(EF) and LV chamber volume are particularly helpful in
initial risk stratification and risk monitoring in the follow-
up of dialysis patients [2].
Recently, an enlarged left atrium (LA) has emerged as
another valuable parameter to predict adverse cardiovascular
outcomes. In general, the LA serves multiple functions, act-
ing as a reservoir during LV systole, a conduit for blood
transiting from the pulmonary veins to the LV during early
diastole, an active contractile chamber that augments LV
filling in late diastole and a suction source that refills itself
in early systole [3]. The LA enlarges in response to two broad
conditions: pressure and volume overload. LA enlargement
due to pressure overload is usually secondary to increased
LA afterload in mitral valve disease or LV dysfunction.
Chronic volume overload associated with conditions such
as valvular regurgitation, arteriovenous fistula and high out-
put states including chronic anemia and athletic heart can
also contribute to chamber enlargement [4]. Such an enlarged
LA is reported to predict adverse cardiovascular outcomes
such as atrial fibrillation, stroke, congestive heart failure and
cardiovascular death in the general population [4].
In patients undergoing peritoneal dialysis (PD), enlarged
LA volume is commonly observed because they have chronic
volume overload and increased afterload due to LV hyper-
trophy [5]. However, there have been few studies to evaluate
the prognostic value of this parameter in patients with ESRD,
particularly those receiving continuous ambulatory peritoneal
dialysis (CAPD). We conducted this observational cohort
study to investigate whether enlarged LA can predict patients’
adverse outcomes and to compare its predictive usefulness
with other echocardiographic parameters in these patients.
Materials and methods
Patients
A total of 344 patients started CAPD at Yonsei University Medical Center
between January 2005 and July 2010. Twenty-eight patients who did not
perform the evaluation of baseline cardiac function due to non-compliance,
cost issue or other personal reasons were excluded. Of the remaining 316
patients, 297 patients underwent echocardiography, whereas other types of
cardiac evaluation such as nuclear imaging were conducted in 19 patients. We
further screened 262 patients who underwent echocardiography within 1
month after the initiation of CAPD for the eligibility of the study excluding
35 patients in whom echocardiography was performed after this period or
before the initiation of CAPD. Of these patients, the exclusion of 46 patients
occurred for the following reasons: PD duration<3 months (n¼ 8), patients<
20 (n¼ 2) or>75 years of age (n¼ 8), hemodialysis or kidney transplantation
before the initiation of PD (n¼ 3), severe systolic dysfunction (EF< 30%,n¼
12), severe mitral stenosis or regurgitation (n¼ 4), underlying malignancy (n
¼ 6), decompensated liver cirrhosis (n¼ 2) and immunosuppressive therapy
due to systemic lupus erythematosus (n¼ 1). Thus, a total of 216 patients were
included in the final analysis. Patients were categorized as icodextrin users if
patients used this solution for >6 months during the study period.
Data collection
At the initiation of PD, patients’ demographic and clinical data such as
age, gender and comorbid conditions were recorded. In addition, labora-
tory parameters such as hemoglobin serum albumin, blood urea nitrogen,
creatinine, calcium, phosphorus and intact parathyroid hormone were
measured at that time. C-reactive protein (CRP) was measured by laser
nephelometry (IMMAGE; Beckman Coulter, Brea, CA). A peritoneal
equilibrium test (PET) was conducted and dialysis adequacy and residual
renal function (RRF) were measured within 2 months after the initiation of
CAPD. Equilibration ratios were measured in a standardized PET that
involved a 2-L 4.25% dextrose dwell with dialyzate samples taken at 0,
2 and 4 h and a plasma sample at 2 h. According to their 4-h dialyzate-to-
plasma ratio (D/P) for creatinine, patients were categorized as one of the
following four peritoneal transport types: high (above 11 SD from the
mean), high average (between the mean and 11 SD), low average (be-
tween the mean and 1 SD) or low (below 1 SD from mean) [6].
Drained dialyzate and 24-h urine (if residual renal function was present)
were collected within 1 day before the PET. Creatinine and urea nitrogen
were measured in blood, urine and drained dialyzate. The residual glomer-
ular filtration rate was calculated as the mean of urinary creatinine and urea
clearances standardized to 1.73 m2 body surface area (BSA). Weekly Kt/V
urea was calculated as the ratio of urinary and 24-h dialyzate urea clear-
ance to total body water [7].
Echocardiography
Echocardiographic examinations were performed using an imaging proto-
col according to the American Society of Echocardiography recommen-
dations [8]. This study was performed with an empty abdomen in CAPD
patients. Standard echocardiography analysis included two dimensional,
M-mode and Doppler flow measurements, using a SONOS 7500 (Philips
Ultrasound, Bothell, WA). The LV systolic function was determined by
the LV EF using a modified biplane Simpson’s method from apical two-
and four-chamber views [9] and systolic dysfunction was defined as EF <
55%. The LV mass was calculated by the method described by Devereux
and Reichek [10]. The LVMI was calculated by dividing LV mass to BSA,
and LV hypertrophy was defined as a LVMI > 131 g/m2 for men and >100
g/m2 for women [11]. The LA volume was assessed by the biplane area–
length method from apical four-chamber and two-chamber views [12].
Measurements were obtained in end systole from the frame preceding mitral
valve opening, and the LA volume was indexed for BSA. According to
population-based studies, a value of 32 mL/m2 was considered as the upper
limit of a normal LAVI [13]. Mitral inflow was assessed with pulse-wave
Doppler echocardiography from the apical four-chamber view. The Doppler
beam was aligned parallel to the direction of flow, and a 1- to 2-mm sample
volume was placed between the tips of the mitral leaflets during diastole.
From the mitral inflow profile, peak E-wave velocity and its deceleration
time, peak A-wave velocity and the isovolumetric relaxation time were
measured [14]. Doppler tissue imaging of the mitral annulus was also
obtained. From the apical four-chamber view, a 1- to 2-mm sample
volume was placed in the septal mitral annulus. The early mitral inflow
velocity to peak mitral annulus velocity (E/E#) ratio >15 was regarded
as an abnormally elevated LV filling pressure [15]. Systolic right ven-
tricular pressure (RVP) was calculated using the modified Bernoulli
equation [4 3 (tricuspid systolic jet)2 1 10 mmHg], and pulmonary
arterial hypertension was defined as RVP > 35 mmHg at rest [16].
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc.,
Chicago, IL). Continuous data were expressed as mean  SD, and cate-
gorical data were expressed as a number (percentage). Comparisons be-
tween the two groups were done by t-test or chi-squared test. The
relationship between paired variables was analyzed using the Pearson
sample correlation coefficient. Cumulative survival curves were generated
by the Kaplan–Meier method, and between-group survival was compared
by the log-rank test. In this analysis, patients who underwent a kidney
transplant or were transferred to hemodialysis during follow-up were cen-
sored at the time of transfer to alternative renal replacement therapy. If a
patient died within 3 months of transfer to hemodialysis, then he or she
was not censored because the early mortality was considered to reflect the
patient’s health status during the period of failing PD treatment. The in-
dependent prognostic value of LAVI for all-cause and cardiovascular (CV)
mortality was analyzed by multiple Cox regression analysis. Hazard ratios
(HR) and 95% confidence intervals (CIs) were calculated with the use of
the estimated regression coefficients and standard errors in the Cox regres-
sion analysis. The predictive value for all-cause and CV mortality was
analyzed by receiver operating characteristic (ROC) curve analysis with
calculated area under the ROC curve (AUC). All probabilities were two
tailed and the level of significance was set at 0.05.
Results
Baseline characteristics of patients
The baseline characteristics of the study population are
shown in Table 1. Of the 216 patients, 99 patients
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(45.8%) had LAVI> 32 mL/m2 and were considered to have
enlarged LA volume. Compared to patients with LAVI  32
mL/m2, those with LAVI > 32 mL/m2 were older (55.3 
13.9 versus 59.8  11.7 years, P ¼ 0.011) and had higher
systolic blood pressure (135.7  16.9 versus 145.6  18.9
mmHg, P < 0.001). In addition, albumin (3.6  0.6 versus
3.4 0.6 g/dL, P¼ 0.048) and hemoglobin (9.3 1.4 versus
8.7  1.4 g/dL, P ¼ 0.003) levels were significantly lower in
patients with LA dilatation. There were no differences in
comorbidities, medications, serum CRP levels, use of icodex-
trin, peritoneal membrane permeability, dialysis adequacy
and residual renal function between the two groups (Table 1).
Compared to patients with low/low average (L/LA)
transporters, serum albumin level (3.7  0.6 versus 3.5 
0.6 g/dL, P ¼ 0.031) was significantly lower in those with
high/high average (H/HA) transporters, whereas LAVI,
blood pressure and the proportion of icodextrin users were
not different between the two groups (data not shown).
Echocardiographic findings
The differences in echocardiographic parameters between
the two groups of patients are presented in Table 2. LV
end-diastolic diameter (49.5  5.1 versus 55.0  6.4 mm,
P < 0.001), LVMI (118.6  31.9 versus 152.7  37.4 g/m2,
P < 0.001), RVP, 27.8  8.4 versus 35.2  11.3 mmHg, P
< 0.001) and the early mitral inflow velocity to peak mitral
annulus velocity (E/E#) ratio (12.3  4.7 versus 18.8  8.2,
P < 0.001) were elevated in patients with LAVI > 32 mL/
m2, while there was no difference in EF between the two
groups. LAVI was positively correlated with LVMI (r ¼
0.636, P < 0.001), RVP (r ¼ 0.425, P < 0.001) and E/E#
ratio (r¼ 0.542, P < 0.001), whereas it was inversely corre-
lated with EF (r ¼ 0.189, P ¼ 0.005) (Figure 1).
Predictors of mortality
During the mean follow-up duration of 26.3  18.6 (3.0 –
69.5) months, 20 patients (9.3%) died, 75% of them from
cardiovascular causes including sudden cardiac death,
acute myocardial infarction or fatal arrhythmias. The 5-
year survival rate was significantly lower in patients with
LAVI > 32 mL/m2 than those with LAVI  32 mL/m2 (69
versus 82%, P ¼ 0.024) (Figure 2). In addition, patients
with LV systolic dysfunction (EF < 55 versus  55%, P ¼
0.017), pulmonary hypertension (RVP > 35 mmHg versus
 35 mmHg, P ¼ 0.021) and LV diastolic dysfunction
(E/E# ratio >15 versus 15, P ¼ 0.014) had a higher
Table 1. Demographic, clinical and biochemical characteristicsa
LAVI  32 mL/m2 (n ¼ 117) LAVI > 32 mL/m2 (n ¼ 99) P-value
Age (years) 55.3 6 13.9 59.8 6 11.7 0.011
Gender (male, n) (%) 61 (52.1%) 60 (60.6%) NS
Body surface area (m2) 1.6 6 0.2 1.7 6 0.2 NS
Diabetes (n, %) 45 (38.5%) 48 (48.5%) NS
Coronary arterial disease
(n, %)
16 (13.7%) 19 (19.2%) NS
Hypertension (n, %) 89 (76.1%) 79 (79.8%) NS
Systolic blood pressure
(mmHg)
135.7 6 16.9 145.6 6 18.9 <0.001
Diastolic blood pressure
(mmHg)
80.7 6 11.4 78.7 6 11.8 NS
Medications use (n, %)
ACE inhibitors or ARBs 74 (63.2%) 63 (63.6%) NS
HMG-CoA reductase
inhibitors
33 (28.2%) 31 (31.3%) NS
Oral active vitamin D 17 (14.5%) 12 (12.1%) NS
Duration of dialysis
(months)
28.3 6 19.4 23.8 6 17.3 NS
Use of icodextrin (n, %) 36 (30.8%) 32 (32.3%) NS
Baseline RRF
(mL/min/1.73 m2)b
3.9 6 3.5 3.6 6 2.6 NS
Urine volume (mL)b 743.1 6 578.9 761.8 6 609.8 NS
Weekly Kt/Vb 2.4 6 0.6 2.3 6 0.6 NS
Peritoneal Kt/Vb 1.6 6 0.4 1.6 6 0.3 NS
Renal Kt/Vb 0.8 6 0.6 0.7 6 0.5 NS
High and HA transporter
(n, %)b
61 (71.8%) 52 (77.6%) NS
CRP (mg/L) 1.2 6 1.8 1.3 6 2.0 NS
Blood urea nitrogen
(mg/dL)
67.7 6 23.9 69.3 6 31.3 NS
Creatinine (mg/dL) 7.7 6 2.6 7.4 6 3.0 NS
Albumin (g/dL) 3.6 6 0.6 3.4 6 0.6 0.048
Hemoglobin (g/dL) 9.3 6 1.4 8.7 6 1.4 0.003
Calcium (mg/dL) 8.3 6 0.8 8.0 6 0.8 0.016
Phosphate (mg/dL) 5.5 6 1.3 5.5 6 1.4 NS
Parathyroid hormone (pg/mL) 176.4 6 164.2 167.8 6 130.6 NS
aACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; RRF, residual renal function; Kt/V, urea clearance; NS, not significant.
Data are presented as n (%) or mean 6 SD.
bDialysis adequacy, RRF and PET were measured in 97 patients with LAVI  32 mL/m2 and in 77 with LAVI > 32 mL/m2.
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mortality. However, survival was not different between
patients with H/HA transporters and those with L/LA trans-
porters (log-rank test, P ¼ 0.26).
Multivariate analysis adjusted for echocardiographic pa-
rameters, diabetes, history of coronary arterial disease, CRP,
serum albumin and hemoglobin showed that increased
LAVI was an independent predictor of all-cause (HR 1.05,
95% CI 1.01–1.10, P ¼ 0.03) and cardiovascular mortality
(HR 1.08, 95% CI 1.02–1.14, P ¼ 0.006). In addition, ele-
vated RVP (HR 1.06, 95% CI 1.00–1.13, P ¼ 0.035), history
of coronary arterial disease (HR 12.30, 95% CI 2.11–71.90, P
¼ 0.005) and increased serum CRP concentrations (HR 1.59,
95% CI 1.20–2.12, P ¼ 0.002) were significantly associated
with an increased risk of all-cause mortality (Tables 3 and 4).
Increased LAVI remained an independent predictive value
for all-cause (HR 1.08, 95% CI 1.03–1.12, P ¼ 0.001) and
cardiovascular mortality (HR 1.10, 95% CI 1.05–1.15, P <
0.001) in a multivariate analysis adjusted for transport types,
whereas high transport status did not have influence on mor-
tality. Furthermore, increased LAVI provided the highest
predictive value for all-cause (AUC ¼ 0.766, P < 0.001)
and cardiovascular mortality (AUC ¼ 0.836, P < 0.001)
among measured echocardiographic parameters (Figure 3).
Discussion
This study showed that increased LAVI was an independ-
ent risk factor for all-cause and cardiovascular mortality in
CAPD patients. In addition, LV systolic dysfunction, pul-
monary hypertension and abnormally elevated LV filling
pressure predicted adverse outcomes in these patients.
Among these echocardiographic parameters, increased
LAVI provided the highest predictive value for all-cause
and cardiovascular mortality.
Recently, much attention has been focused on LA vol-
ume as an indicator of CV outcomes in addition to LV
Fig. 1. Relationship between LAVI with EF (A), left ventricular volume index (B), RVP (C) and the early mitral inflow velocity to peak mitral annulus
velocity (E/E#) ratio (D). Data are correlation coefficients (r) and P-values.
Table 2. Echocardiographic parametersa
LAVI  32 mL/m2
(n ¼ 117)
LAVI > 32 mL/m2
(n ¼ 99) P-value
EF (%) 62.4 6 10.0 59.5 6 12.4 NS
LVEDD (mm) 49.5 6 5.1 55.0 6 6.4 <0.001
LVM (g) 195.1 6 56.8 257.5 6 67.7 <0.001
LVM index (g/m2) 118.6 6 31.9 152.7 6 37.4 <0.001
LAV (mL) 39.2 6 10.0 77.9 6 23.7 <0.001
LAV index (mL/m2) 23.8 6 5.2 46.5 6 14.5 <0.001
RVP (mmHg) 27.8 6 8.4 35.2 6 11.3 <0.001
E/E# 12.3 6 4.7 18.8 6 8.2 <0.001
E/A 0.9 6 0.3 1.0 6 0.6 0.02
aLVEDD, left ventricular end-diastolic diameter; LVM, left ventricular
mass; LAV, left atrial volume; E/E’, ratio of early mitral inflow velocity
to peak mitral annulus velocity; E/A, ratio of early to late transmitral flow
velocity; NS, not significant. Data are presented as mean 6 SD.
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hypertrophy and LV systolic dysfunction. LA dilation in-
duces stasis and the development of atrial fibrillation,
which predisposes the patient to thromboembolism [17].
Atrial stretch facilitates neurohormonal activation and the
secretion of atrial natriuretic peptide, which may have a
role in the development of atrial dysrhythmias. The loss
of organized atrial activity can also directly precipitate con-
gestive heart failure (CHF) [18]. The LA is not only a
passive passage for blood to the LV, but it also affects
LV filling because of its contractile function. The LA con-
tributes up to 30% of the total LV stroke volume in normal
individuals; this atrial contribution is of particular impor-
tance in the context of LV dysfunction to maintain ad-
equate LV stroke volume [3].
Many previous studies have shown that an enlarged LA is
predictive of adverse outcomes in patients with cardiovascu-
lar conditions such as known cardiomyopathy [19], acute
myocardial infarction [20] or pre-existing atrial fibrillation
[17]. However, few studies that evaluate the relationship be-
tween LAVI and cardiovascular outcomes in ESRD
patients have been conducted. Ozdogan et al. evaluated the
predictive value of increased LA volume in ESRD patients,
but their study population mostly consisted of hemodialysis
patients [21, 22]. In addition, LV systolic and diastolic func-
tions were not included in the multivariable Cox regression
Table 3. Multiple Cox regression models of LAVI for all-cause mortalitya
Covariates HR (95% CI) P-value
EF 1.03 (0.97–1.10) 0.34
LVMI 1.01 (0.99–1.02) 0.64
LAVI 1.05 (1.01–1.10) 0.03
RVP 1.06 (1.00–1.13) 0.035
E/E# 0.97 (0.89–1.05) 0.44
Coronary artery disease 12.30 (2.11–71.90) 0.005
Diabetes 0.82 (0.20–3.61) 0.82
CRP 1.59 (1.20–2.12) 0.002
Albumin 0.68 (0.19–2.42) 0.57
Hemoglobin 1.15 (0.71–1.86) 0.57
aData are reported as HR and 95% CI. E/E#, ratio of early mitral inflow
velocity to peak mitral annulus velocity.
Fig. 2. Kaplan–Meier survival curves for all-cause mortality according to (A) LAVI, (B) EF, (C) RVP and (D) the early mitral inflow velocity to peak
mitral annulus velocity (E/E#) ratio.
Table 4. Multiple Cox regression models of LAVI for cardiovascular
mortalitya
Covariates HR (95% CI) P-value
EF 0.99 (0.93–1.05) 0.67
LVMI 1.00 (0.97–1.02) 0.78
LAVI 1.08 (1.02–1.14) 0.006
RVP 1.10 (1.03–1.18) 0.008
E/E# 0.95 (0.86–1.04) 0.28
Diabetes 0.89 (0.14–5.61) 0.89
CRP 1.52 (1.00–2.30) 0.05
Albumin 0.32 (0.07–1.62) 0.17
Hemoglobin 1.16 (0.69–1.96) 0.58
aData are reported as HR and 95% CI. LAVI; E/E#, ratio of early mitral
inflow velocity to peak mitral annulus velocity.
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analysis. Therefore, it was uncertain whether LAVI could
predict adverse outcomes independently of other echocardio-
graphic parameters. Our study clearly showed that increased
LAVI independently predicted all-cause and cardiovascular
mortality in patients with CAPD and provided the highest
predictive value among these parameters.
Our findings may have therapeutic implications for pa-
tients undergoing CAPD. It has been reported that extrac-
ellular volume was greater in CAPD patients and that left
ventricular hypertrophy (LVH) was more severe and com-
mon in those patients than in hemodialysis (HD) patients
[5]. In addition, previous studies showed that such a volume
overload was a significant predictor of both all-cause and
cardiovascular mortality in ESRD patients [23, 24]. A num-
ber of studies have suggested the importance of fluid man-
agement in ESRD patients. Particularly, in the European
Automated Peritoneal Dialysis Outcome Study, peritoneal
ultrafiltration volume >750 mL/day was significantly asso-
ciated with higher survival in anuric patients [25], suggest-
ing the importance of volume control in these patients. In
the present study, we can surmise that patients with en-
larged LA were volume expanded, which might explain
the higher mortality rate in these patients. Therefore, more
attention should be paid to better control of fluid overload in
patients with enlarged LA.
In previous studies, LVH has been shown to be an im-
portant prognostic factor for cardiovascular events in ESRD
patients [2]. An increase in LV mass and cardiac fibrosis has
profound consequences in patients with CKD. Sudden car-
diac death, linked to abnormal electrical conduction in the
distorted and fibrotic ventricle, is a prominent mortal event
in ESRD patients. The late stage of LVH and cardiac fibrosis
leads to both diastolic and systolic dysfunction and ulti-
mately to clinically recognizable CHF, which has a definite
adverse effect on long-term survival in CKD [26]. In con-
trast, LVH did not predict adverse outcomes in our study
patients. Such discrepant findings can be partly explained by
the different study population; previous studies mostly con-
sisted of HD patients. Moreover, in those studies, LAVI was
not considered in the analyses. Our findings also suggest that
patients with PD are more likely to be volume expanded
compared to those with HD and that their cardiovascular
risk is more affected by volume status than LVH. In addition
to LVH, Wang et al. [27] reported that E/E# ratio measured
by Doppler echocardiography provided an independent
prognostic value for long-term mortality and CV death in
CAPD patients. Multiple Doppler echocardiographic varia-
bles have been used to assess LV diastolic function. How-
ever, these variables reflect the beat-to-beat interaction of LV
filling pressure and ventricular compliance, making them
sensitive to rapid alterations in ventricular preload and after-
load [28]. On the other hand, it is reported that LA size is a
more stable indicator to reflect the duration and severity of
diastolic dysfunction than any other echocardiographic pa-
rameter although it is largely determined by the same factors
that influence diastolic LV filling [29]. In addition, Moller
et al. [20] showed that LAVI was superior to conventional
Doppler indices of diastolic function for predicting mortality
in patients with acute myocardial infarction. In line with
these findings, we demonstrated that increased LAVI was
an independent risk factor for all-cause and CV mortality,
whereas elevated E/E# ratio was not, suggesting that LAVI is
a more reliable predictor in patients with PD.
There has been much controversy on whether patients
with high transport have worse prognosis compared to those
with low transport types. Some authors reported that a high
transport status was associated with a poor outcome [30],
while others failed to demonstrate such finding [31]. How-
ever, functional and structural cardiac functions can be in-
fluenced by transport status because high transport status has
been suggested as a common cause of ultrafiltration failure
[32]. On the contrary, in the present study, LAVI, LV sys-
tolic function and LVMI were not different between patients
with H/HA transporters and those with L/LA transporters.
Furthermore, multivariate analysis adjusted for transport sta-
tus showed that an increased LAVI remained as an inde-
pendent predictor of all-cause and cardiovascular
mortality, whereas H/HA transport status was not. Interest-
ingly, inherent high peritoneal transport may differ from
acquired high transport that is generally attributed to the
composition of PD solutions and infectious complications,
as suggested by Reyes et al. [33]. In their study, such inher-
ent high peritoneal transport was not associated with patient
survival. Those findings may partly explain the lack of rela-
tionship between the peritoneal membrane permeability and
mortality in our study.
Fig. 3. ROC curve analyses for (A) all-cause mortality and (B) cardiovascular mortality with calculated AUCs. E/E#, ratio of early mitral inflow velocity
to peak mitral annulus velocity.
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Our study has several limitations. First, there was an
inherent limitation in the observational study design. Sec-
ond, we could not assess other indicators of extracellular
volume such as NT-proBNP measured by immunoassay or
extracellular fluid volume/total body water ratio measured
by multifrequency electric bioimpedance. However, these
assessment tools have not yet been validated in ESRD
patients, although some studies showed that elevated NT-
proBNP or fluid overload assessed by bioimpedence anal-
ysis was predictive of adverse outcomes in this population
[23]. Third, baseline RRF was not considered in the multi-
variate analyses because it was not measured within 2
months after the initiation of PD in 42 patients (19.4%)
due to inadequate urine collection and non-compliance.
In these patients, RRF was measured between 3 and 12
months. Owing to this inconsistent time of measurement,
their data for RRF could not be included in the analyses.
Fourth, echocardiographic parameters might act as con-
founding factors to other parameters because most of those
parameters were correlated with each other. Nevertheless,
LAVI was the strongest predictor for all-cause and CV
mortality in a multivariable Cox model, even after adjust-
ment of such parameters and ROC curve analyses. Finally,
echocardiographic examinations were performed only at
the initiation of PD. Whether such echocardiographic find-
ings would remain unaltered during the follow-up period is
unknown. Serial follow-up of echocardiography may be of
help in understanding the natural history of LA remodeling
in ESRD. Whether regression of LA size translates into
improved CV outcomes requires further studies.
In conclusion, this is the first study, to our knowledge,
showing that increased LAVI predicts adverse outcomes
better than other echocardiographic, clinical or biochemical
parameters in patients with CAPD. Our findings suggest
that measurement of LAVI may be of help in risk stratifi-
cation and in providing therapeutic direction for the
management of CAPD patients.
Acknowledgements. This paper was supported by a grant of the Korea
Healthcare Technology R&D Project of the Ministry for Health, Welfare
& Family Affairs, Republic of Korea (A084001).
Conflict of interest statement. None declared.
References
1. K/DOQI clinical practice guidelines for cardiovascular disease in di-
alysis patients. Am J Kidney Dis 2005; 45: S1–S153
2. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular
hypertrophy in and survival of patients receiving hemodialysis: follow-
up of an interventional study. J Am Soc Nephrol 2001; 12: 2759–2767
3. Leung DY, Boyd A, Ng AA et al. Echocardiographic evaluation of left
atrial size and function: current understanding, pathophysiologic corre-
lates, and prognostic implications. Am Heart J 2008; 156: 1056–1064
4. Abhayaratna WP, Seward JB, Appleton CP et al. Left atrial size:
physiologic determinants and clinical applications. J Am Coll Cardiol
2006; 47: 2357–2363
5. Enia G, Mallamaci F, Benedetto FA et al. Long-term CAPD patients
are volume expanded and display more severe left ventricular hyper-
trophy than haemodialysis patients. Nephrol Dial Transplant 2001;
16: 1459–1464
6. Twardowski ZJ. Clinical value of standardized equilibration tests in
CAPD patients. Blood Purif 1989; 7: 95–108
7. Watson PE, Watson ID, Batt RD. Total body water volumes for adult
males and females estimated from simple anthropometric measure-
ments. Am J Clin Nutr 1980; 33: 27–39
8. Schiller NB, Shah PM, Crawford M et al. Recommendations for quanti-
tation of the left ventricle by two-dimensional echocardiography. Amer-
ican Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardiograms.
J Am Soc Echocardiogr 1989; 2: 358–367
9. Otterstad JE, Froeland G, St John Sutton M. Accuracy and reproduci-
bility of biplane two-dimensional echocardiographic measurements of
left ventricular dimensions and function. Eur Heart J 1997; 18: 507–513
10. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assess-
ment of left ventricular hypertrophy: comparison to necropsy findings.
Am J Cardiol 1986; 57: 450–458
11. Liao Y, Cooper RS, Durazo-Arvizu R et al. Prediction of mortality
risk by different methods of indexation for left ventricular mass. J Am
Coll Cardiol 1997; 29: 641–647
12. Lester SJ, Ryan EW, Schiller NB et al. Best method in clinical prac-
tice and in research studies to determine left atrial size. Am J Cardiol
1999; 84: 829–832
13. Pritchett AM, Mahoney DW, Jacobsen SJ et al. Diastolic dysfunction
and left atrial volume: a population-based study. J Am Coll Cardiol
2005; 45: 87–92
14. Oki T, Tabata T, Yamada H et al. Clinical application of pulsed
Doppler tissue imaging for assessing abnormal left ventricular relax-
ation. Am J Cardiol 1997; 79: 921–928
15. Sohn DW, Chai IH, Lee DJ et al. Assessment of mitral annulus
velocity by Doppler tissue imaging in the evaluation of left ventricular
diastolic function. J Am Coll Cardiol 1997; 30: 474–480
16. Unal A, Sipahioglu M, Oguz F et al. Pulmonary hypertension in peri-
toneal dialysis patients: prevalence and risk factors. Perit Dial Int 2009;
29: 191–198
17. Tsang TS, Abhayaratna WP, Barnes ME et al. Prediction of cardio-
vascular outcomes with left atrial size: is volume superior to area or
diameter? J Am Coll Cardiol 2006; 47: 1018–1023
18. Kizer JR, Bella JN, Palmieri V et al.Left atrial diameter as an independent
predictor of first clinical cardiovascular events in middle-aged and elderly
adults: the Strong Heart Study (SHS). Am Heart J 2006; 151: 412–418
19. Sabharwal N, Cemin R, Rajan K et al. Usefulness of left atrial volume as
a predictor of mortality in patients with ischemic cardiomyopathy. Am
J Cardiol 2004; 94: 760–763
20. Moller JE, Hillis GS, Oh JK et al. Left atrial volume: a powerful pre-
dictor of survival after acute myocardial infarction. Circulation 2003;
107: 2207–2212
21. Ozdogan O, Kayikcioglu M, Asci G et al. Left atrial volume predicts
mortality in low-risk dialysis population on long-term low-salt diet. Am
Heart J 2010; 159: 1089–1094
22. Tripepi G, Benedetto FA, Mallamaci F et al. Left atrial volume in
end-stage renal disease: a prospective cohort study. J Hypertens
2006; 24: 1173–1180
23. Paniagua R, Ventura MD, Avila-Diaz M et al.NT-proBNP, fluid volume
overload and dialysis modality are independent predictors of mortality in
ESRD patients. Nephrol Dial Transplant 2010; 25: 551–557
24. Cheng LT, Gao YL, Qin C et al. Volume overhydration is related to
endothelial dysfunction in continuous ambulatory peritoneal dial-
ysis patients. Perit Dial Int 2008; 28: 397–402
25. Davies SJ, Brown EA, Reigel W et al. What is the link between
poor ultrafiltration and increased mortality in anuric patients on
automated peritoneal dialysis? Analysis of data from EAPOS. Perit
Dial Int 2006; 26: 458–465
26. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass
in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009;
4 (Suppl 1): S79–S91
27. Wang AY, Wang M, Lam CW et al. Left ventricular filling pressure
by Doppler echocardiography in patients with end-stage renal
disease. Hypertension 2008; 52: 107–114
28. Hurrell DG, Nishimura RA, Ilstrup DM et al. Utility of preload
alteration in assessment of left ventricular filling pressure by
Doppler echocardiography: a simultaneous catheterization and Doppler
echocardiographic study. J Am Coll Cardiol 1997; 30: 459–467
3738 S.J. Kim et al.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on N
ovem
ber 24, 2013
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
29. Simek CL, Feldman MD, Haber HL et al. Relationship between left
ventricular wall thickness and left atrial size: comparison with other
measures of diastolic function. J Am Soc Echocardiogr 1995; 8: 37–47
30. Wang T, Heimburger O, Waniewski J et al. Increased peritoneal per-
meability is associated with decreased fluid and small-solute removal
and higher mortality in CAPD patients. Nephrol Dial Transplant
1998; 13: 1242–1249
31. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport
rate an independent risk factor for CAPD mortality? Kidney Int
2000; 57: 314–320
32. Bakkaloglu SA, Saygili A, Sever L et al. Impact of peritoneal
transport characteristics on cardiac function in paediatric peritoneal
dialysis patients: a Turkish Pediatric Peritoneal Dialysis
Study Group (TUPEPD) report. Nephrol Dial Transplant 2010;
25: 2296–2303
33. Reyes MJ, Bajo MA, Hevia C et al. Inherent high peritoneal
transport and ultrafiltration deficiency: their mid-term clinical
relevance. Nephrol Dial Transplant 2007; 22: 218–223
Received for publication: 15.12.10; Accepted in revised form: 11.2.11
Nephrol Dial Transplant (2011) 26: 3739–3744
doi: 10.1093/ndt/gfr170
Advance Access publication 15 April 2011
Variability of effluent cancer antigen 125 and interleukin-6
determination in peritoneal dialysis patients
Deirisa Lopes Barreto1, Annemieke M. Coester1, Marlies Noordzij2, Watske Smit1,3, Dirk G. Struijk1,3,
Susan Rogers3, Dirk R. de Waart4 and Raymond T. Krediet1
1Division of Nephrology, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam,
The Netherlands, 2Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, 3Dianet Foundation Amsterdam-Utrecht, The Netherlands and 4Department of Experimental Hepatology, Academic
Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Correspondence and offprint requests to: Deirisa Lopes Barreto; E-mail: d.lopesbarreto@amc.uva.nl
Abstract
Background. Cancer antigen (CA) 125 is a glycoprotein
that provides data on the state of the peritoneal membrane
in peritoneal dialysis (PD). Interleukin-6 (IL-6) acts as a
mediator in acute-phase responses. The study evaluated the
usefulness of CA125 and IL-6 in random effluent samples,
by assessing their variability in individual patients during
clinical practice at the outpatient department.
Methods. This longitudinal prospective study was con-
ducted from 2007 till 2009. Participants included 52 stable
PD patients aged 18 years. Effluent samples were
obtained during regular outpatient visits and appearance
rates (ARs) were calculated. Inter- and intra-individual var-
iability was determined by the coefficient of variation
(CV). A linear mixed model was used to analyse time
courses. Furthermore, release patterns of these effluent
markers were studied.
Results. CA125-AR of short-term patients (24 months)
ranged from 39.2 to 766.7 U/min and IL-6-AR from 15.5 to
220.0 pg/min. Long-term patients (25 months) had a
CA125-AR of 7.3–1534.0 U/min and IL-6-AR of 6.9–
956.4 pg/min. Overall, CVintra was 15% in effluent
CA125-AR and 28% in IL-6-AR. Intermediate sampling
during a 4-h dwell showed a linear increase of CA125
and IL-6 effluent concentrations. The trend of CA125-AR
was different (P ¼ 0.001) between short- and long-term
patients. A negative relationship was found between
CA125 (r ¼ 0.44, P ¼ 0.02) and PD duration.
Conclusions. The clinical relevance of effluent CA125
determinations from an unstandardized dwell during every
outpatient visit is reasonable, as judged from the CVintra.
The inferior CVintra values of ARs as compared to effluent
values indicate that ARs should only be calculated under
standardized conditions. A single IL-6 measurement, as a
predictor of outcome, should be interpreted cautiously.
Keywords: biomarkers; cancer antigen 125; interleukin-6; mesothelial
cells; peritoneal dialysis
Introduction
Cancer antigen (CA) 125 is a high molecular weight (220
kDa) glycoprotein that is constitutively produced by
peritoneal mesothelial cells in vitro [1]. The number of
mesothelial cells in peritoneal effluent of stable peritoneal
dialysis (PD) patients is proportional to peritoneal dialysate
CA125 concentration [2]. Therefore, it can be regarded as a
marker for the mesothelial cell mass in stable PD patients
and thus provides data on the state of the peritoneal mem-
brane in vivo [3]. Extremely low CA125 concentrations
have been found in effluent of patients preceding the diag-
nosis of peritoneal sclerosis [4]. This is supportive to the
contention that a loss of mesothelial cells is implicated in
the pathogenesis of peritoneal sclerosis, a serious com-
plication of long-term PD [5]. The small day-to-day
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